Leap therapeutics to present positive new data from the distinguish study of dkn-01 plus tislelizumab at the asco gi cancers symposium

Cambridge, mass., jan. 18, 2022 /prnewswire/ -- leap therapeutics, inc. (nasdaq:lptx), a biotechnology company focused  on developing targeted and immuno-oncology therapeutics, today announced the company will be presenting updated data from the distinguish study, a phase 2a clinical trial evaluating leap's anti-dickkopf-1 (dkk1) antibody, dkn-01, in combination with tislelizumab, beigene's anti-pd-1 antibody, in patients with gastric or gastroesophageal junction cancer (g/gej), at the american society of clinical oncology (asco) gastrointestinal (gi) cancers symposium being held on january 20-22, 2022.
LPTX Ratings Summary
LPTX Quant Ranking